Arrhythmias & electrophysiology
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study
Authors' conclusion
In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol.
Study context
- Population
- US Medicare beneficiaries aged ≥65 years with AF who began apixaban or rivaroxaban (2012–2018) and then initiated study antiarrhythmic drugs
- Participants
- 91,590 beneficiaries
- Exposure
- Amiodarone vs flecainide or sotalol during apixaban or rivaroxaban use
- Amiodaronen = 54,977
- Flecainide or sotaloln = 36,613reference
- Outcome
- Time to bleeding-related hospitalization
Methodological detailspropensity score overlap weighting
- Propensity score overlap weighting
Main finding
As reported in the abstract
Bleeding-related hospitalizations
Each group vs flecainide or sotalolRate difference, events per 1000 person-years (95% CI)
Amiodarone
17.5(12.0–23.0)
Each group vs flecainide or sotalolHazard ratio (95% CI)
Amiodarone
1.44(1.27–1.63)
Observational data: associations, not effects.
Secondary outcomes
Ischemic stroke or systemic embolism
- Incidence did not increase
- Propensity score overlap weighting
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation : A Retrospective Cohort Study. Ann Intern Med. Published 23 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →